Cloning Benefits Oversold, Says Stem-Cell Scientist

December 19, 2006

The medical promise of therapeutic cloning has been oversold and its unreasonably high profile risks turning the public against more promising aspects of stem-cell research, according to one of Britain’s most respected experts in the field. Cloning research “clearly upsets the general public” yet it has limited potential for treating disease and adds little to scientific understanding of human biology, according to Professor Austin Smith of the University of Cambridge. (The Times)